The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012: Practice parameters with an evidence-based systematic review and meta-analyses

R. Nisha Aurora, David A. Kristo, Sabin R. Bista, James A. Rowley, Rochelle S. Zak, Kenneth R. Casey, Carin I. Lamm, Sharon L. Tracy, Richard S. Rosenberg

Research output: Contribution to journalReview article

194 Citations (Scopus)

Abstract

A systematic literature review and meta-analyses (where appropriate) were performed to update the previous AASM practice parameters on the treatments, both dopaminergic and other, of RLS and PLMD. A considerable amount of literature has been published since these previous reviews were performed, necessitating an update of the corresponding practice parameters. Therapies with a ST ANDARD level of recommendation include pramipexole and ropinirole. Therapies with a GUIDELINE level of recommendation include levodopa with dopa decarboxylase inhibitor, opioids, gabapentin enacarbil, and cabergoline (which has additional caveats for use). Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation. The committee recommends a ST ANDARD AGAINST the use of pergolide because of the risks of heart valve damage. Therapies for RLS secondary to ESRD, neuropathy, and superficial venous insufficiency are discussed. Lastly, therapies for PLMD are reviewed. However, it should be mentioned that because PLMD therapy typically mimics RLS therapy, the primary focus of this review is therapy for idiopathic RLS.

Original languageEnglish (US)
Pages (from-to)1039-1062
Number of pages24
JournalSleep
Volume35
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Nocturnal Myoclonus Syndrome
Restless Legs Syndrome
Meta-Analysis
Therapeutics
Dopa Decarboxylase
Pergolide
Venous Insufficiency
Heart Valves
Carbamazepine
Clonidine
Levodopa
Ferritins
Opioid Analgesics
Chronic Kidney Failure
Iron

Keywords

  • PLMD
  • Periodic limb movement disorder
  • RLS
  • Restless legs syndrome
  • Sleep-related movement disorders

ASJC Scopus subject areas

  • Clinical Neurology
  • Physiology (medical)

Cite this

The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012 : Practice parameters with an evidence-based systematic review and meta-analyses. / Aurora, R. Nisha; Kristo, David A.; Bista, Sabin R.; Rowley, James A.; Zak, Rochelle S.; Casey, Kenneth R.; Lamm, Carin I.; Tracy, Sharon L.; Rosenberg, Richard S.

In: Sleep, Vol. 35, No. 8, 01.08.2012, p. 1039-1062.

Research output: Contribution to journalReview article

Aurora, R. Nisha ; Kristo, David A. ; Bista, Sabin R. ; Rowley, James A. ; Zak, Rochelle S. ; Casey, Kenneth R. ; Lamm, Carin I. ; Tracy, Sharon L. ; Rosenberg, Richard S. / The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012 : Practice parameters with an evidence-based systematic review and meta-analyses. In: Sleep. 2012 ; Vol. 35, No. 8. pp. 1039-1062.
@article{9f76e3a6338d4f2f8c38d09a1dcab0e3,
title = "The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012: Practice parameters with an evidence-based systematic review and meta-analyses",
abstract = "A systematic literature review and meta-analyses (where appropriate) were performed to update the previous AASM practice parameters on the treatments, both dopaminergic and other, of RLS and PLMD. A considerable amount of literature has been published since these previous reviews were performed, necessitating an update of the corresponding practice parameters. Therapies with a ST ANDARD level of recommendation include pramipexole and ropinirole. Therapies with a GUIDELINE level of recommendation include levodopa with dopa decarboxylase inhibitor, opioids, gabapentin enacarbil, and cabergoline (which has additional caveats for use). Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation. The committee recommends a ST ANDARD AGAINST the use of pergolide because of the risks of heart valve damage. Therapies for RLS secondary to ESRD, neuropathy, and superficial venous insufficiency are discussed. Lastly, therapies for PLMD are reviewed. However, it should be mentioned that because PLMD therapy typically mimics RLS therapy, the primary focus of this review is therapy for idiopathic RLS.",
keywords = "PLMD, Periodic limb movement disorder, RLS, Restless legs syndrome, Sleep-related movement disorders",
author = "Aurora, {R. Nisha} and Kristo, {David A.} and Bista, {Sabin R.} and Rowley, {James A.} and Zak, {Rochelle S.} and Casey, {Kenneth R.} and Lamm, {Carin I.} and Tracy, {Sharon L.} and Rosenberg, {Richard S.}",
year = "2012",
month = "8",
day = "1",
doi = "10.5665/sleep.1988",
language = "English (US)",
volume = "35",
pages = "1039--1062",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "8",

}

TY - JOUR

T1 - The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012

T2 - Practice parameters with an evidence-based systematic review and meta-analyses

AU - Aurora, R. Nisha

AU - Kristo, David A.

AU - Bista, Sabin R.

AU - Rowley, James A.

AU - Zak, Rochelle S.

AU - Casey, Kenneth R.

AU - Lamm, Carin I.

AU - Tracy, Sharon L.

AU - Rosenberg, Richard S.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - A systematic literature review and meta-analyses (where appropriate) were performed to update the previous AASM practice parameters on the treatments, both dopaminergic and other, of RLS and PLMD. A considerable amount of literature has been published since these previous reviews were performed, necessitating an update of the corresponding practice parameters. Therapies with a ST ANDARD level of recommendation include pramipexole and ropinirole. Therapies with a GUIDELINE level of recommendation include levodopa with dopa decarboxylase inhibitor, opioids, gabapentin enacarbil, and cabergoline (which has additional caveats for use). Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation. The committee recommends a ST ANDARD AGAINST the use of pergolide because of the risks of heart valve damage. Therapies for RLS secondary to ESRD, neuropathy, and superficial venous insufficiency are discussed. Lastly, therapies for PLMD are reviewed. However, it should be mentioned that because PLMD therapy typically mimics RLS therapy, the primary focus of this review is therapy for idiopathic RLS.

AB - A systematic literature review and meta-analyses (where appropriate) were performed to update the previous AASM practice parameters on the treatments, both dopaminergic and other, of RLS and PLMD. A considerable amount of literature has been published since these previous reviews were performed, necessitating an update of the corresponding practice parameters. Therapies with a ST ANDARD level of recommendation include pramipexole and ropinirole. Therapies with a GUIDELINE level of recommendation include levodopa with dopa decarboxylase inhibitor, opioids, gabapentin enacarbil, and cabergoline (which has additional caveats for use). Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation. The committee recommends a ST ANDARD AGAINST the use of pergolide because of the risks of heart valve damage. Therapies for RLS secondary to ESRD, neuropathy, and superficial venous insufficiency are discussed. Lastly, therapies for PLMD are reviewed. However, it should be mentioned that because PLMD therapy typically mimics RLS therapy, the primary focus of this review is therapy for idiopathic RLS.

KW - PLMD

KW - Periodic limb movement disorder

KW - RLS

KW - Restless legs syndrome

KW - Sleep-related movement disorders

UR - http://www.scopus.com/inward/record.url?scp=84864762471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864762471&partnerID=8YFLogxK

U2 - 10.5665/sleep.1988

DO - 10.5665/sleep.1988

M3 - Review article

C2 - 22851801

AN - SCOPUS:84864762471

VL - 35

SP - 1039

EP - 1062

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 8

ER -